Literature DB >> 11504311

Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.

J Akervall1, E Brun, M Dictor, J Wennerberg.   

Abstract

The aim of this study was to investigate whether there is an association between overexpression of cyclin D1 and response to therapy. Immunohistochemical overexpression of cyclin D1 was determined in paraffin-embedded specimens from diagnostic biopsies of 89 primary cases of squamous cell carcinoma of the head and neck (SCCHN), using a polyclonal antiserum. The tumor response rates were estimated after curative treatment (i.e. surgery and/or radiotherapy and/or chemotherapy). Patients whose tumors were overexpressing cyclin D1 showed complete or partial response to neoadjuvant chemotherapy with cisplatin/5-FU. In addition, a majority of cyclin D1 negative tumors did not respond at all to this treatment (p = 0.02, Fisher's exact test). This study indicates that immunohistochemical assessment of cyclin D1 expression in SCCHN could be a new predictive marker to select a subgroup of patients that will benefit from neoadjuvant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504311     DOI: 10.1080/028418601750288244

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  8 in total

1.  Targeting the RB-pathway in cancer therapy.

Authors:  Erik S Knudsen; Jean Y J Wang
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

2.  EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Authors:  Tim N Beck; Rachel Georgopoulos; Elena I Shagisultanova; David Sarcu; Elizabeth A Handorf; Cara Dubyk; Miriam N Lango; John A Ridge; Igor Astsaturov; Ilya G Serebriiskii; Barbara A Burtness; Ranee Mehra; Erica A Golemis
Journal:  Mol Cancer Ther       Date:  2016-08-09       Impact factor: 6.261

Review 3.  Proteomic identification of a direct role for cyclin d1 in DNA damage repair.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; David M Livingston; Piotr Sicinski
Journal:  Cancer Res       Date:  2012-08-22       Impact factor: 12.701

4.  Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer.

Authors:  Bhavna Kumar; Kitrina G Cordell; Nisha D'Silva; Mark E Prince; Meredith E Adams; Susan G Fisher; Gregory T Wolf; Thomas E Carey; Carol R Bradford
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-04

5.  Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer.

Authors:  Go Nakajima; Kazuhiko Hayashi; Yaguang Xi; Kenji Kudo; Kazumi Uchida; Ken Takasaki; Masakazu Yamamoto; Jingfang Ju
Journal:  Cancer Genomics Proteomics       Date:  2006-10       Impact factor: 4.069

6.  Characteristics of head and neck squamous cell carcinoma cell Lines reflect human tumor biology independent of primary etiologies and HPV status.

Authors:  Thankam S Nair; Trey B Thomas; Lucy Yang; Bala Naveen Kakaraparthi; Anna C Morris; Alanna M Clark; Lora P Campredon; Andrew F Brouwer; Marisa C Eisenberg; Rafael Meza; Thomas E Carey
Journal:  Transl Oncol       Date:  2020-06-20       Impact factor: 4.243

Review 7.  Biomarker driven treatment of head and neck squamous cell cancer.

Authors:  Nnamdi Eze; Ying-Chun Lo; Barbara Burtness
Journal:  Cancers Head Neck       Date:  2017-08-29

8.  Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.

Authors:  Gabrielle van Caloen; Sandra Schmitz; Cédric van Marcke; Xavier Caignet; Antonella Mendola; Sébastien Pyr Dit Ruys; Pierre P Roger; Didier Vertommen; Jean-Pascal Machiels
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.